menu
    • menu
    [{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"LifeNet Health","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Dermacell","moa":"Progenitor cell","graph1":"Podiatry","graph2":"Phase II\/ Phase III","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ LifeNet Health","highestDevelopmentStatusID":"9","companyTruncated":"Baylor College of Medicine \/ LifeNet Health"},{"orgOrder":0,"company":"Lavior Pharma Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Lavior","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II\/ Phase III","graph3":"Lavior Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Lavior Pharma Inc. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lavior Pharma Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Xianglei Tangzu Gao","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II\/ Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oneness Biotech \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oneness Biotech

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Oneness Biotech

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xianglei Tangzu Gao

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulc...

                            Details : Xianglei Tangzu Gao is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : Xianglei Tangzu Gao

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lavior Pharma Inc.

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Lavior Pharma Inc.

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lavior

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Restoring Tissue and Evaluating Novel Treatments for Efficacy in Wounds

                            Details : Lavior is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 07, 2022

                            Lead Product(s) : Lavior

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Baylor College of Medicine

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Baylor College of Medicine

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermacell

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II/ Phase III

                            Sponsor : LifeNet Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Fo...

                            Details : Dermacell is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 26, 2018

                            Lead Product(s) : Dermacell

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : LifeNet Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth